Skip to main content
Journal cover image

Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia.

Publication ,  Journal Article
Larue, SM; Fox, MH; Ogilvie, GK; Page, RL; Getzy, DM; Thrall, DE; Johnson, JL; Dewhirst, MW; Gillette, EL
Published in: Int J Hyperthermia
1999

Kinetic parameters including potential doubling time (Tpot), duration of S phase (Ts), labelling index (LI), and DNA index (DI) were obtained from 42 dogs with previously untreated lymphoma. Standard flow cytometric techniques using BrdUrd were employed. All dogs were treated with L-asparaginase and remission was induced in 26 dogs, which were then randomized to receive chemotherapy only (doxorubicin [DOX] alone or with lonidamine) or chemotherapy plus whole body hyperthermia (WBH). Dogs were treated every 3 weeks for up to five treatments and evaluated every 3 weeks for evidence of tumour recurrence. Within this subset of animals there was no difference in outcome based on treatment group. Median values for Tpot, Ts and LI were 3.4 days, 7.23 h and 12.49%, respectively. Dogs that had tumours with LI > or = 20% had a shorter time until recurrence than dogs with tumours characterized by LI < 20%. In dogs treated only with chemotherapy, dogs bearing tumours with longer than median Tpot and Ts values and lower than median LI had significantly longer remission duration than dogs with more rapidly proliferating tumours. Dogs treated only with chemotherapy, which had longer than median Tpot and Ts values and lower than median LI, had significantly longer remission duration than all other dogs in the study. The mechanisms in which kinetics are associated with response to chemotherapy are not clear and vary depending on tumour type and treatment regimen. More work is needed to understand factors involved in cell killing during in vivo hyperthermia.

Duke Scholars

Published In

Int J Hyperthermia

DOI

ISSN

0265-6736

Publication Date

1999

Volume

15

Issue

6

Start / End Page

475 / 486

Location

England

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Lymphoma
  • Indazoles
  • Hyperthermia, Induced
  • Doxorubicin
  • Dogs
  • Dog Diseases
  • Combined Modality Therapy
  • Cell Cycle
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Larue, S. M., Fox, M. H., Ogilvie, G. K., Page, R. L., Getzy, D. M., Thrall, D. E., … Gillette, E. L. (1999). Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia. Int J Hyperthermia, 15(6), 475–486. https://doi.org/10.1080/026567399285477
Larue, S. M., M. H. Fox, G. K. Ogilvie, R. L. Page, D. M. Getzy, D. E. Thrall, J. L. Johnson, M. W. Dewhirst, and E. L. Gillette. “Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia.Int J Hyperthermia 15, no. 6 (1999): 475–86. https://doi.org/10.1080/026567399285477.
Larue SM, Fox MH, Ogilvie GK, Page RL, Getzy DM, Thrall DE, et al. Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia. Int J Hyperthermia. 1999;15(6):475–86.
Larue, S. M., et al. “Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia.Int J Hyperthermia, vol. 15, no. 6, 1999, pp. 475–86. Pubmed, doi:10.1080/026567399285477.
Larue SM, Fox MH, Ogilvie GK, Page RL, Getzy DM, Thrall DE, Johnson JL, Dewhirst MW, Gillette EL. Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia. Int J Hyperthermia. 1999;15(6):475–486.
Journal cover image

Published In

Int J Hyperthermia

DOI

ISSN

0265-6736

Publication Date

1999

Volume

15

Issue

6

Start / End Page

475 / 486

Location

England

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Lymphoma
  • Indazoles
  • Hyperthermia, Induced
  • Doxorubicin
  • Dogs
  • Dog Diseases
  • Combined Modality Therapy
  • Cell Cycle